Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials

Dimitrios Kotsos, Carin Hazenberg, Thomas Pabst, Patrycja Gradowska, Markus Manz, Johan Maertens, Carlos Graux, Marie-Christiane Vekemans, Bjorn Gjertsen, Soren Lehmann, Catharina Van Elssen, Peter Valk, Edo Vellenga, Gert J. Ossenkoppele, Bob Lowenberg, Marc Raaijmakers, Gerwin A. Huls, Jurjen Versluis

Blood (2025) 146 (Supplement 1): 2517.

https://doi.org/10.1182/blood-2025-2517

Published: 2025

Journal Articles

Post-remission immunotherapy with vididencel for a measurable residual disease defined high-risk sub-group of adult patients with Acute Myeloid Leukemia in first complete hematological remission: Updated results of the european advance II study demonstrate robust safety, relapse-free and overall survival benefit.

Arjan Van de Loosdrecht, Eva-Maria Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Janine Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jacqueline Cloos, Hester Van Zeeburg, Jeroen Rovers, Alex Karlsson-Parra, Tariq Mughal, Bjorn Gjertsen

Blood (2025) 146 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2025-1647

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Single-cell multi-omics uncovers differentiation-dependent transcriptional programs shaping epigenetic subgroups in AML

Blood (2025) 146 (Supplement 1): 5005.

https://doi.org/10.1182/blood-2025-5005

Published: 2025

Journal Articles

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 451.

https://doi.org/10.1182/blood-2025-451

Published: 2025

Journal Articles

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Blood (2025) 146 (Supplement 1): 343.

https://doi.org/10.1182/blood-2025-343

Published: 2025

Journal Articles

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Blood (2024) 144 (Supplement 1): 844.

https://doi.org/10.1182/blood-2024-202362

Published: 2024

Journal Articles

Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA + CD200 - leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Blood (2024) 144 (Supplement 1): 1565.

https://doi.org/10.1182/blood-2024-200093

Published: 2024

Journal Articles

Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Blood (2024) 144 (Supplement 1): 639.

https://doi.org/10.1182/blood-2024-200415

Published: 2024

Journal Articles

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Arjan A. van de Loosdrecht, Eva-Maria Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jacqueline Cloos, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2024) 144 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2024-201374

Published: 2024

Journal Articles

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan A. van de Loosdrecht, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2023) 142 (Supplement 1): 769.

https://doi.org/10.1182/blood-2023-185532

Published: 2023

Journal Articles

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Luca Guarnera, Soren Lehmann, Konstanze Döhner, Hartmut Döhner, Uwe Platzbecker, Nigel H. Russell, Richard Dillon, Ian Thomas, Gert Ossenkoppele, Marco Vignetti, Edoardo la Sala, Alfonso Piciocchi, Angela Villaverde Ramiro, Laura Tur, Carmelo Gurnari, Lars Bullinger, Jesús María Hernández-Rivas, Maria Teresa Voso

Blood (2023) 142 (Supplement 1): 727.

https://doi.org/10.1182/blood-2023-185121

Published: 2023

Journal Articles

Epigenetic Classification of Acute Myeloid Leukemia Revealed By Genome-Wide Chromatin Profiling

Blood (2023) 142 (Supplement 1): 836.

https://doi.org/10.1182/blood-2023-180336

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Hester Van Zeeburg, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jeroen Rovers, Bjorn T. Gjertsen, Arjan A. van de Loosdrecht

Blood (2023) 142 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2023-188573

Published: 2023

Journal Articles

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Blood (2023) 142 (1): 73–89.

https://doi.org/10.1182/blood.2022016896

Published: 2023

Includes: Supplemental data

Journal Articles

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Blood (2023) 141 (7): 800–805.

https://doi.org/10.1182/blood.2022017874

Published: 2023

Includes: Supplemental data

Journal Articles

Data-Driven Molecular Hallmarks of Acute Myeloid Leukemia: Biological, Prognostic and Therapeutic Implications

Tom Erkers, Francesco Marabita, Nona Struyf, Mattias Vesterlund, Tojo James, Cornelia Arnroth, Anna Bohlin, Sofia Bengtzén, Albin Österroos, Matthias Stahl, Rozbeh Jafari, Lukas Orre, Yudi Pawitan, Brinton Seashore-Ludlow, Janne Lehtiö, Sören Lehmann, Päivi Östling, Olli Kallioniemi

Blood (2022) 140 (Supplement 1): 6299.

https://doi.org/10.1182/blood-2022-163046

Published: 2022

Journal Articles

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Sören Lehmann, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 1714–1715.

https://doi.org/10.1182/blood-2022-162169

Published: 2022

Journal Articles

Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing

Nona Struyf, Cornelia Arnroth, Stephanie Sunandar, Anna Bohlin, Sofia Bengtzén, Sören Lehmann, Olli Kallioniemi, Päivi Östling, Brinton Seashore-Ludlow, Tom Erkers

Blood (2022) 140 (Supplement 1): 6290.

https://doi.org/10.1182/blood-2022-157262

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Single-cell multi-omics uncovers differentiation-dependent transcriptional programs shaping epigenetic subgroups in AML

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA + CD200 - leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Epigenetic Classification of Acute Myeloid Leukemia Revealed By Genome-Wide Chromatin Profiling

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Data-Driven Molecular Hallmarks of Acute Myeloid Leukemia: Biological, Prognostic and Therapeutic Implications

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only